Related Experiment Videos
Targeted antiestrogens for the prevention of breast cancer
1Department of Surgery, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA.
Abstract:
This commentary explores the recent experience with and the basis for the use of selective estrogen receptor modulators (SERMs) to prevent breast cancer. Chemoprevention has been a goal for many years. As newer agents are unveiled, they will continue to be tested against tamoxifen, the current standard for the treatment and prevention of breast cancer. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. The Study of Tamoxifen and Raloxifene (STAR) trial and prior prevention studies will be discussed in an attempt understand the bridge from the laboratory to the clinic.
Insights
Selective estrogen receptor modulators (SERMs) show promise for breast cancer prevention. Raloxifene offers osteoporosis treatment alongside breast cancer risk reduction, with ongoing studies comparing it to tamoxifen.
Area of Science:
- Oncology
- Pharmacology
Background:
- Selective estrogen receptor modulators (SERMs) are investigated for breast cancer prevention.
- Tamoxifen is the current standard for breast cancer treatment and prevention.
Purpose of the Study:
- To explore the use of SERMs for breast cancer chemoprevention.
- To review recent experiences and the scientific basis for SERM utilization in breast cancer prevention.
Main Methods:
- Discussion of the Study of Tamoxifen and Raloxifene (STAR) trial.
- Review of prior breast cancer prevention studies.
- Analysis of the transition from laboratory findings to clinical application.
Main Results:
- Raloxifene demonstrates potential for osteoporosis treatment with breast cancer prevention benefits.
- SERMs are being evaluated against tamoxifen, the established standard.
Conclusions:
- SERMs, like raloxifene, represent a promising avenue for breast cancer chemoprevention.
- Further research and clinical trials are essential to solidify the role of SERMs in breast cancer prevention strategies.